# Lanadelumab (Genetical Recombination) S.C. Injection 300mg Pen (タクザイロ皮下注３００ｍｇペン)

> Prescription product approved in Japan and listed on the NHI drug price list (YJ code 4490407G2020). Nifuji Pharma sources it for licensed healthcare providers, institutions, and distributors; availability, documentation, and export eligibility are confirmed on inquiry.

- **YJ code:** 4490407G2020
- **Product name (Japanese):** タクザイロ皮下注３００ｍｇペン
- **English title:** Lanadelumab (Genetical Recombination) S.C. Injection 300mg Pen
- **Active ingredient:** ラナデルマブ（遺伝子組換え）
- **Active ingredient (INN):** Lanadelumab (Genetical Recombination)
- **Strength / unit:** ３００ｍｇ２ｍＬ１キット
- **Route:** Injection (注射薬)
- **Therapeutic category:** 44 Antiallergic agents (アレルギー用薬) › 449 Other antiallergic agents (その他のアレルギー用薬)
- **Manufacturer:** Takeda Pharmaceutical (武田薬品工業)
- **NHI price (reference only):** JPY 1288729 per ３００ｍｇ２ｍＬ１キット
- **Regulatory status:** Approved in Japan; listed on the NHI drug price list
- **Web page:** https://www.nifujipharma.com/drugs/4490407G2020
- **JSON:** https://www.nifujipharma.com/api/drugs/4490407G2020

## How to request a quotation

Submit the contact form with the product name, quantity, and destination country: https://www.nifujipharma.com/?product=Lanadelumab%20(Genetical%20Recombination)%20S.C.%20Injection%20300mg%20Pen%20(%E3%82%BF%E3%82%AF%E3%82%B6%E3%82%A4%E3%83%AD%E7%9A%AE%E4%B8%8B%E6%B3%A8%EF%BC%93%EF%BC%90%EF%BC%90%EF%BD%8D%EF%BD%87%E3%83%9A%E3%83%B3)%20%2F%20YJ%204490407G2020#contact

Quotes are for qualified business customers only (licensed healthcare providers, medical institutions, distributors). Payment is by bank transfer in Japanese Yen. Product collection typically takes 2-4 weeks after order confirmation, followed by export procedures and shipping.

## Other listed products with Lanadelumab (Genetical Recombination)

- [Lanadelumab (Genetical Recombination) S.C. Injection 300mg Syringe (タクザイロ皮下注３００ｍｇシリンジ)](https://www.nifujipharma.com/drugs/4490407G1023) — ３００ｍｇ２ｍＬ１筒, Takeda Pharmaceutical